Animal Intestinal Health Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Animal Intestinal Health Market was valued at USD 4.5 billion in 2024 and is estimated to grow at a CAGR of 8.3% to reach USD 9.8 billion by 2034 due to a surge in gastrointestinal conditions among animals, including chronic digestive disorders and inflammation-related issues. With growing concerns around animal wellness, the demand for preventive care is accelerating, especially in livestock management. Maintaining optimal gut health has become a crucial factor not just for disease prevention but also for improving feed efficiency and overall animal productivity. As meat, dairy, and egg consumption continues to rise globally, particularly in fast-developing economies, demand for healthy livestock has become more urgent and commercially important.
As global agricultural practices shift away from antibiotic-heavy treatments, natural alternatives such as probiotics and prebiotics are gaining substantial momentum. These nutritional supplements offer sustainable solutions for maintaining digestive balance and immune performance in animals. The market also reflects a growing interest in holistic, non-therapeutic approaches to animal husbandry. Digestive health, now viewed as central to the economic and biological performance of livestock and companion animals alike, is driving innovation and product development across nutritional and pharmaceutical segments.
Based on product category, nutrition-based solutions held the largest share in 2024, generating USD 2.9 billion in revenue. This growth stems from increasing awareness among farmers, pet owners, and veterinarians about the value of balanced diets and gut-supporting nutrients. Preventive approaches are becoming more popular as they reduce the dependency on drug-based treatments. Companies have ramped up efforts to educate stakeholders on the long-term benefits of dietary supplementation, encouraging greater adoption of gut health enhancers in both commercial farms and homes.
Livestock animals represent the leading segment by animal type are projected to generate USD 5.6 billion by 2034. This segment includes cattle, poultry, and swine integral to the global protein supply. Healthy intestinal function in livestock ensures higher productivity, improved immune response, and reduced mortality, making gut health management a key part of efficient farming. As consumer demand for meat and dairy continues to climb, maintaining intestinal well-being in livestock becomes essential to sustaining food security and economic stability.
United States Animal Intestinal Health Market generated USD 1.6 billion in 2024, driven by increasing consumer awareness about pet health, a surge in companion animal adoption, and the growing emphasis on preventive veterinary care. The steady rise in pet ownership across the country is a key factor contributing to the expansion of the market. More households treat pets as family members, spending on their wellness and nutrition. With intestinal health playing a vital role in the overall well-being and longevity of animals, pet owners are becoming more proactive in choosing gut-supportive diets, supplements, and functional products.
Key players in the market include AdvaCarePharma, Evonik, Lallemand, Zoetis, Kerry Group, Phibro Animal Health, Kemin, Cargill, ADM, Koninklijke DSM, PetAg, Adisseo, Karyotica Biologicals, PRN Pharmacal, and BioChem. These companies are investing in targeted R&D for developing advanced prebiotics, synbiotics, and gut-boosting enzymes. Many are expanding their global presence through partnerships and strategic acquisitions, while also launching awareness campaigns to promote early adoption of preventive gut health solutions in animals.
Companies Mentioned
Adisseo, ADM, AdvaCarePharma, BioChem, Cargill, Evonik, Karyotica Biologicals, Kemin, Kerry Group, Koninklijke DSM, Lallemand, PetAg, Phibro Animal Health, PRN Pharmacal, Zoetis
As global agricultural practices shift away from antibiotic-heavy treatments, natural alternatives such as probiotics and prebiotics are gaining substantial momentum. These nutritional supplements offer sustainable solutions for maintaining digestive balance and immune performance in animals. The market also reflects a growing interest in holistic, non-therapeutic approaches to animal husbandry. Digestive health, now viewed as central to the economic and biological performance of livestock and companion animals alike, is driving innovation and product development across nutritional and pharmaceutical segments.
Based on product category, nutrition-based solutions held the largest share in 2024, generating USD 2.9 billion in revenue. This growth stems from increasing awareness among farmers, pet owners, and veterinarians about the value of balanced diets and gut-supporting nutrients. Preventive approaches are becoming more popular as they reduce the dependency on drug-based treatments. Companies have ramped up efforts to educate stakeholders on the long-term benefits of dietary supplementation, encouraging greater adoption of gut health enhancers in both commercial farms and homes.
Livestock animals represent the leading segment by animal type are projected to generate USD 5.6 billion by 2034. This segment includes cattle, poultry, and swine integral to the global protein supply. Healthy intestinal function in livestock ensures higher productivity, improved immune response, and reduced mortality, making gut health management a key part of efficient farming. As consumer demand for meat and dairy continues to climb, maintaining intestinal well-being in livestock becomes essential to sustaining food security and economic stability.
United States Animal Intestinal Health Market generated USD 1.6 billion in 2024, driven by increasing consumer awareness about pet health, a surge in companion animal adoption, and the growing emphasis on preventive veterinary care. The steady rise in pet ownership across the country is a key factor contributing to the expansion of the market. More households treat pets as family members, spending on their wellness and nutrition. With intestinal health playing a vital role in the overall well-being and longevity of animals, pet owners are becoming more proactive in choosing gut-supportive diets, supplements, and functional products.
Key players in the market include AdvaCarePharma, Evonik, Lallemand, Zoetis, Kerry Group, Phibro Animal Health, Kemin, Cargill, ADM, Koninklijke DSM, PetAg, Adisseo, Karyotica Biologicals, PRN Pharmacal, and BioChem. These companies are investing in targeted R&D for developing advanced prebiotics, synbiotics, and gut-boosting enzymes. Many are expanding their global presence through partnerships and strategic acquisitions, while also launching awareness campaigns to promote early adoption of preventive gut health solutions in animals.
Companies Mentioned
Adisseo, ADM, AdvaCarePharma, BioChem, Cargill, Evonik, Karyotica Biologicals, Kemin, Kerry Group, Koninklijke DSM, Lallemand, PetAg, Phibro Animal Health, PRN Pharmacal, Zoetis
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing awareness of animal gut microbiome
3.2.1.2 Growing demand for animal healthcare products
3.2.1.3 Rising prevalence of animal intestinal diseases
3.2.2 Industry pitfalls and challenges
3.2.2.1 Regulatory challenges and reliability concerns
3.2.2.2 Lack of awareness among pet owners and farmers
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Trump administration tariffs
3.5.1 Impact on trade
3.5.1.1 Trade volume disruptions
3.5.1.2 Retaliatory measures
3.5.2 Impact on the Industry
3.5.2.1 Supply-side impact (raw materials)
3.5.2.1.1 Price volatility in key materials
3.5.2.1.2 Supply chain restructuring
3.5.2.1.3 Production cost implications
3.5.2.2 Demand-side impact (selling price)
3.5.2.2.1 Price transmission to end markets
3.5.2.2.2 Market share dynamics
3.5.2.2.3 Consumer response patterns
3.5.3 Key companies impacted
3.5.4 Strategic industry responses
3.5.4.1 Supply chain reconfiguration
3.5.4.2 Pricing and product strategies
3.5.4.3 Policy engagement
3.5.5 Outlook and future considerations
3.6 Porter's analysis
3.7 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT TYPE, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Nutritions
5.2.1 Probiotics
5.2.2 Prebiotics
5.2.3 Synbiotics
5.2.4 Enzymes
5.2.5 Immunomodulators
5.2.6 Other nutrition
5.3 Pharmaceuticals
5.3.1 Antibiotics
5.3.2 Other pharmaceuticals
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY ANIMAL TYPE, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Companion animals
6.2.1 Dogs
6.2.2 Cats
6.2.3 Horses
6.2.4 Other companion animals
6.3 Livestock animals
6.3.1 Cattle
6.3.2 Swine
6.3.3 Poultry
6.3.4 Other livestock animals
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY FUNCTION, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 Preventive care
7.3 Disease treatment
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY MODE OF ADMINISTRATION, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 Feed/water additives
8.3 Other modes of administration
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 Veterinary hospitals
9.3 E-commerce
9.4 Retail pharmacies
9.5 Other distribution channels
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Adisseo
11.2 ADM
11.3 AdvaCarePharma
11.4 BioChem
11.5 Cargill
11.6 Evonik
11.7 Karyotica Biologicals
11.8 Kemin
11.9 Kerry Group
11.10 Koninklijke DSM
11.11 Lallemand
11.12 PetAg
11.13 Phibro Animal Health
11.14 PRN Pharmacal
11.15 Zoetis
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing awareness of animal gut microbiome
3.2.1.2 Growing demand for animal healthcare products
3.2.1.3 Rising prevalence of animal intestinal diseases
3.2.2 Industry pitfalls and challenges
3.2.2.1 Regulatory challenges and reliability concerns
3.2.2.2 Lack of awareness among pet owners and farmers
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Trump administration tariffs
3.5.1 Impact on trade
3.5.1.1 Trade volume disruptions
3.5.1.2 Retaliatory measures
3.5.2 Impact on the Industry
3.5.2.1 Supply-side impact (raw materials)
3.5.2.1.1 Price volatility in key materials
3.5.2.1.2 Supply chain restructuring
3.5.2.1.3 Production cost implications
3.5.2.2 Demand-side impact (selling price)
3.5.2.2.1 Price transmission to end markets
3.5.2.2.2 Market share dynamics
3.5.2.2.3 Consumer response patterns
3.5.3 Key companies impacted
3.5.4 Strategic industry responses
3.5.4.1 Supply chain reconfiguration
3.5.4.2 Pricing and product strategies
3.5.4.3 Policy engagement
3.5.5 Outlook and future considerations
3.6 Porter's analysis
3.7 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT TYPE, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Nutritions
5.2.1 Probiotics
5.2.2 Prebiotics
5.2.3 Synbiotics
5.2.4 Enzymes
5.2.5 Immunomodulators
5.2.6 Other nutrition
5.3 Pharmaceuticals
5.3.1 Antibiotics
5.3.2 Other pharmaceuticals
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY ANIMAL TYPE, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Companion animals
6.2.1 Dogs
6.2.2 Cats
6.2.3 Horses
6.2.4 Other companion animals
6.3 Livestock animals
6.3.1 Cattle
6.3.2 Swine
6.3.3 Poultry
6.3.4 Other livestock animals
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY FUNCTION, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 Preventive care
7.3 Disease treatment
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY MODE OF ADMINISTRATION, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 Feed/water additives
8.3 Other modes of administration
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 Veterinary hospitals
9.3 E-commerce
9.4 Retail pharmacies
9.5 Other distribution channels
CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
CHAPTER 11 COMPANY PROFILES
11.1 Adisseo
11.2 ADM
11.3 AdvaCarePharma
11.4 BioChem
11.5 Cargill
11.6 Evonik
11.7 Karyotica Biologicals
11.8 Kemin
11.9 Kerry Group
11.10 Koninklijke DSM
11.11 Lallemand
11.12 PetAg
11.13 Phibro Animal Health
11.14 PRN Pharmacal
11.15 Zoetis
